Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL.

Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS.

Leuk Lymphoma. 2020 Jan 23:1-8. doi: 10.1080/10428194.2020.1716221. [Epub ahead of print]

PMID:
31971032
2.

An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement.

Sunderland AJ, Steiner RE, Al Zahrani M, Pinnix CC, Dabaja BS, Gunther JR, Nastoupil LJ, Jerkeman M, Joske D, Cull G, El-Galaly T, Villa D, Cheah CY.

Cancer Med. 2020 Jan;9(2):663-670. doi: 10.1002/cam4.2732. Epub 2019 Dec 5.

3.

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma.

Strati P, Ahmed MAA, Fowler N, Nastoupil LJ, Samaniego F, Fayad LE, Hagemeister FB, Romaguera JE, Rodriguez A, Wang M, Westin JR, Cheah C, Noorani M, Feng L, Davis RE, Neelapu SS.

Haematologica. 2019 Oct 10. pii: haematol.2019.230649. doi: 10.3324/haematol.2019.230649. [Epub ahead of print]

4.

De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.

Hu B, Nastoupil LJ, Loghavi S, Westin JR, Thakral B, Fayad LE, Hagemeister F, Neelapu S, Samaniego F, Lee HJ, Wang ML, Fanale M, Fowler N, Oki Y.

Leuk Lymphoma. 2020 Feb;61(2):328-336. doi: 10.1080/10428194.2019.1663418. Epub 2019 Sep 18.

PMID:
31533521
5.

Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.

Matasar MJ, Luminari S, Barr PM, Barta SK, Danilov AV, Hill BT, Phillips TJ, Jerkeman M, Magagnoli M, Nastoupil LJ, Persky DO, Okosun J.

Oncologist. 2019 Nov;24(11):e1236-e1250. doi: 10.1634/theoncologist.2019-0138. Epub 2019 Jul 25. Review.

6.

Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma.

Andraos TY, Ayoub Z, Nastoupil LJ, Milgrom SA, Pinnix CC, Ng SP, Gunther JR, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Dabaja BS.

Leuk Lymphoma. 2019 Dec;60(13):3258-3265. doi: 10.1080/10428194.2019.1627535. Epub 2019 Jun 24.

PMID:
31234671
7.

Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs.

Zackon AYL, Ayers AA, Yeager KA, Somma ML, Friedberg JW, Flowers CR, Nastoupil LJ.

Leuk Lymphoma. 2019 Oct;60(10):2356-2364. doi: 10.1080/10428194.2019.1594217. Epub 2019 Jun 4.

PMID:
31164024
8.

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection.

Strati P, Nastoupil LJ, Fayad LE, Samaniego F, Adkins S, Neelapu SS.

Blood. 2019 Jun 27;133(26):2800-2802. doi: 10.1182/blood.2019000888. Epub 2019 May 17. No abstract available.

PMID:
31101626
9.

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.

Strati P, Nastoupil LJ, Davis RE, Fayad LE, Fowler N, Hagemeister FB, Kwak L, Oki Y, Wang M, Westin J, Ruben CE, Wesson ET, Piekarz R, Fanale MA, Lee HJ.

Haematologica. 2020 Jan;105(1):e26-e28. doi: 10.3324/haematol.2019.220012. Epub 2019 May 9. No abstract available.

10.

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma.

Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS.

Blood Adv. 2019 May 14;3(9):1356-1367. doi: 10.1182/bloodadvances.2018029140.

11.

Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy.

Ayoub Z, Andraos T, Milgrom SA, Pinnix CC, Dabaja BS, Ng SP, Gunther JR, Khoury JD, Fowler NH, Neelapu SS, Samaniego F, Fayad LE, Nastoupil LJ.

Leuk Lymphoma. 2019 Oct;60(10):2432-2440. doi: 10.1080/10428194.2019.1597081. Epub 2019 Apr 3.

PMID:
30942648
12.

Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.

Becnel MR, Nastoupil LJ, Samaniego F, Davis RE, You MJ, Green M, Hagemeister FB, Fanale MA, Fayad LE, Westin JR, Wang M, Oki Y, Forbes SG, Feng L, Neelapu SS, Fowler NH.

Br J Haematol. 2019 Jun;185(5):874-882. doi: 10.1111/bjh.15843. Epub 2019 Mar 28.

13.

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH.

Lancet Haematol. 2019 Feb;6(2):e100-e109. doi: 10.1016/S2352-3026(18)30216-3.

PMID:
30709431
14.

Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue.

Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Fayad LE, Khoury JD, Medeiros LJ, Dabaja BS, Nastoupil LJ.

Clin Lymphoma Myeloma Leuk. 2019 Apr;19(4):244-250. doi: 10.1016/j.clml.2018.12.016. Epub 2019 Jan 3.

PMID:
30686775
15.

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY.

Ann Hematol. 2019 May;98(5):1169-1176. doi: 10.1007/s00277-018-3571-7. Epub 2019 Jan 8.

PMID:
30617643
16.

Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms.

Ludmir EB, Gutschenritter T, Pinnix CC, Gunther JR, Nastoupil LJ, Khoury JD, Medeiros LJ, Dabaja BS, Milgrom SA.

Onco Targets Ther. 2018 Dec 10;11:8937-8942. doi: 10.2147/OTT.S159843. eCollection 2018.

17.

Novel immunotherapy approaches to follicular lymphoma.

Flowers CR, Leonard JP, Nastoupil LJ.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):194-199. doi: 10.1182/asheducation-2018.1.194. Review.

18.

Sequencing of therapies in relapsed follicular lymphoma.

Nastoupil LJ, Flowers CR, Leonard JP.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):189-193. doi: 10.1182/asheducation-2018.1.189. Review.

19.

Where to start? Upfront therapy for follicular lymphoma in 2018.

Leonard JP, Nastoupil LJ, Flowers CR.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):185-188. doi: 10.1182/asheducation-2018.1.185. Review.

20.

Next-generation therapy for follicular lymphoma.

Nastoupil LJ.

Blood. 2018 Oct 4;132(14):1465-1467. doi: 10.1182/blood-2018-08-868117. No abstract available.

PMID:
30287467
21.

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.

Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, Strasfeld L, Flowers CR.

J Clin Oncol. 2018 Oct 20;36(30):3043-3054. doi: 10.1200/JCO.18.00374. Epub 2018 Sep 4.

PMID:
30179565
22.

Point: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?

Nastoupil LJ.

Oncology (Williston Park). 2018 Aug 15;32(8):404-7. No abstract available.

23.

Recent insights into large granular lymphocytic leukemia.

Nastoupil LJ.

Clin Adv Hematol Oncol. 2018 Jul;16(7):469-471. No abstract available.

PMID:
30067616
24.

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study.

de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, Dunbar M, Enschede SH, Nolan C, Petrich AM, Ross JA, Salem AH, Verdugo M, Agarwal S, Zhou L, Kozloff M, Nastoupil LJ, Flowers CR.

Ann Oncol. 2018 Sep 1;29(9):1932-1938. doi: 10.1093/annonc/mdy256.

25.

Disparities in survival by insurance status in follicular lymphoma.

Goldstein JS, Nastoupil LJ, Han X, Jemal A, Ward E, Flowers CR.

Blood. 2018 Sep 13;132(11):1159-1166. doi: 10.1182/blood-2018-03-839035. Epub 2018 Jul 24.

26.

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis.

Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, Fayad LE, Neelapu SS, Cheah CY.

Oncotarget. 2018 Jun 22;9(48):28897-28902. doi: 10.18632/oncotarget.25622. eCollection 2018 Jun 22.

27.

Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.

Chihara D, Oki Y, Fanale MA, Westin JR, Nastoupil LJ, Neelapu S, Fayad L, Fowler NH, Cheah CY.

Br J Haematol. 2019 Apr;185(2):334-338. doi: 10.1111/bjh.15444. Epub 2018 Jul 5. No abstract available.

PMID:
29978452
28.

The need to assess financial adverse events.

Nastoupil LJ, Prasad V, Flowers CR.

Lancet Haematol. 2018 Nov;5(11):e508-e509. doi: 10.1016/S2352-3026(18)30072-3. Epub 2018 Jun 12. No abstract available.

PMID:
29907551
29.

Follicular Lymphoma: Past, Present, and Future.

Becnel MR, Nastoupil LJ.

Curr Treat Options Oncol. 2018 May 24;19(7):32. doi: 10.1007/s11864-018-0550-0. Review.

PMID:
29796824
30.

Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure<sup/>.

Ludmir EB, Milgrom SA, Pinnix CC, Gunther JR, Westin J, Oki Y, Fayad LE, Medeiros LJ, Dabaja BS, Nastoupil LJ.

Leuk Lymphoma. 2018 Dec;59(12):2896-2903. doi: 10.1080/10428194.2018.1460825. Epub 2018 Apr 26.

PMID:
29697005
31.

Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy.

Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):530-540. doi: 10.1016/j.ijrobp.2018.03.003. Epub 2018 Mar 14.

PMID:
29681481
32.

Disparities in lymphoma on the basis of race, gender, HIV status, and sexual orientation.

Becnel M, Flowers CR, Nastoupil LJ.

Ann Lymphoma. 2017 Nov;1. pii: 8. doi: 10.21037/aol.2017.11.01. Epub 2017 Nov 17.

33.

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.

Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Oki Y.

PLoS One. 2018 Mar 14;13(3):e0191461. doi: 10.1371/journal.pone.0191461. eCollection 2018.

34.

Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update.

Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR.

J Clin Oncol. 2018 May 10;36(14):1443-1453. doi: 10.1200/JCO.2017.77.6211. Epub 2018 Feb 20.

PMID:
29461916
35.

Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma.

Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1146-1154. doi: 10.1016/j.ijrobp.2018.01.003. Epub 2018 Jan 6.

PMID:
29452771
36.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network.

J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.

37.

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions.

Pinnix CC, Andraos TY, Dabaja B, Milgrom S, Smith G, Chihara D, Ng A, Fayad LE, Oki Y, Neelapu S, Westin J, Rodriguez MA, Nastoupil LJ.

Adv Radiat Oncol. 2017 Apr 22;2(3):370-380. doi: 10.1016/j.adro.2017.04.004. eCollection 2017 Jul-Sep.

38.

Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility.

Guidot DM, Switchenko JM, Nastoupil LJ, Koff JL, Blum KA, Maly J, Flowers CR, Cohen JB.

Leuk Lymphoma. 2018 Apr;59(4):888-895. doi: 10.1080/10428194.2017.1361032. Epub 2017 Aug 10.

39.

Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y.

Leuk Lymphoma. 2018 Apr;59(4):863-870. doi: 10.1080/10428194.2017.1359741. Epub 2017 Aug 9.

PMID:
28792260
40.

Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma<sup/>.

Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, Young KH, Deng L, Medeiros LJ, Dong W, Allen PK, Andraos TY, Fowler NH, Nastoupil LJ, Oki Y, Fayad LE, Turturro F, Neelapu SS, Westin J, Hagemeister FB, Rodriguez MA, Pinnix CC.

Leuk Lymphoma. 2017 Dec;58(12):2833-2844. doi: 10.1080/10428194.2017.1312381. Epub 2017 May 9.

41.

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.

Nastoupil LJ, McLaughlin P, Feng L, Neelapu SS, Samaniego F, Hagemeister FB, Ayala A, Romaguera JE, Goy AH, Neal E, Wang M, Fayad L, Fanale MA, Oki Y, Westin JR, Rodriguez MA, Cabanillas F, Fowler NH.

Br J Haematol. 2017 Apr;177(2):263-270. doi: 10.1111/bjh.14541. Epub 2017 Mar 24.

42.

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma.

Oncale MB, Maymani H, Nastoupil LJ.

Blood Lymphat Cancer. 2017 Feb 16;7:1-7. doi: 10.2147/BLCTT.S110665. eCollection 2017. Review.

43.

The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y.

Br J Haematol. 2017 Mar;176(5):750-758. doi: 10.1111/bjh.14477. Epub 2016 Dec 16.

44.

Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients.

Rai A, Nastoupil LJ, Williams JN, Lipscomb J, Ward KC, Howard DH, Lee D, Flowers CR.

Leuk Lymphoma. 2017 Jul;58(7):1570-1580. doi: 10.1080/10428194.2016.1253836. Epub 2016 Nov 10.

45.

Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.

Cheah CY, Nastoupil LJ, McLaughlin P, Fanale MA, Neelapu SS, Fayad LE, Hagemeister FB, Fowler NH.

Br J Haematol. 2016 Nov;175(3):531-533. doi: 10.1111/bjh.13863. Epub 2015 Dec 18. No abstract available.

PMID:
26683805
46.

Relations Between Residential Proximity to EPA-Designated Toxic Release Sites and Diffuse Large B-Cell Lymphoma Incidence.

Bulka C, Nastoupil LJ, Koff JL, Bernal-Mizrachi L, Ward KC, Williams JN, Bayakly AR, Switchenko JM, Waller LA, Flowers CR.

South Med J. 2016 Oct;109(10):606-614.

47.

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.

Chen Y, Neelapu S, Feng L, Bi W, Yang TH, Wang M, Fanale MA, Westin JR, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Fowler NH, McLaughlin P, Cabanillas F, Oki Y, Nastoupil LJ, Rodriguez A.

Br J Haematol. 2016 Oct;175(2):290-299. doi: 10.1111/bjh.14237. Epub 2016 Jul 22.

PMID:
27448187
48.

Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.

Chihara D, Westin JR, Miranda RN, Cheah CY, Oki Y, Turturro F, Romaguera JE, Neelapu SS, Nastoupil LJ, Fayad LE, Rodriguez MA, Fowler NH, Orlowski RZ, Wang M, Hagemeister FB, Medeiros LJ, Fanale MA.

Br J Haematol. 2017 Nov;179(3):503-506. doi: 10.1111/bjh.14226. Epub 2016 Jul 5. No abstract available.

49.

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.

Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ.

Cancer. 2016 Oct 15;122(20):3145-3151. doi: 10.1002/cncr.30173. Epub 2016 Jun 28.

50.

Role of the tumor microenvironment in mature B-cell lymphoid malignancies.

Fowler NH, Cheah CY, Gascoyne RD, Gribben J, Neelapu SS, Ghia P, Bollard C, Ansell S, Curran M, Wilson WH, O'Brien S, Grant C, Little R, Zenz T, Nastoupil LJ, Dunleavy K.

Haematologica. 2016 May;101(5):531-40. doi: 10.3324/haematol.2015.139493. Review.

Supplemental Content

Loading ...
Support Center